Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

(2014) P. G. Richardson et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

(2013) Maria T. Petrucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

(2011) B Mohty et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data

(2011) D. Pulte et al.   ONCOLOGIST

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

(2010) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA